Inventor · disambiguated record
Stephen Edward Rapecki
Also filed as: RAPECKI STEPHEN E · RAPECKI STEPHEN EDWARD
28 granted patents·19 pending applications·180 citations·filing 2004–2025
96Inventor score
Top patents by PatentIndex Score
47 records- 0197US10590197B2Antibody molecules which bind CD22UCB BIOPHARMA SPRL·Filed 2016·Granted Mar 17, 2020·14 cites·7 claims
- 0296US10705094B2TNF receptor signaling modulator assayUCB Biopharma SRL·Filed 2015·Granted Jul 7, 2020·9 cites·18 claims
- 0396US10358493B2Bispecific format suitable for use in high-through-put screeningUCB BIOPHARMA SPRL·Filed 2015·Granted Jul 23, 2019·14 cites·9 claims
- 0495US10883996B2Methods of identifying signaling modulators of the trimeric TNFaUCB Biopharma SRL·Filed 2015·Granted Jan 5, 2021·7 cites·5 claims
- 0593US11448655B2Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptorsUCB Biopharma SRL·Filed 2020·Granted Sep 20, 2022·2 cites·17 claims
- 0693US10829566B2Method employing bispecific antibodiesUCB BIOPHARMA SPRL·Filed 2016·Granted Nov 10, 2020·8 cites·17 claims
- 0793US10775385B2Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimersUCB BIOPHARMA SPRL·Filed 2015·Granted Sep 15, 2020·7 cites·4 claims
- 0893US10618957B2Antibody molecules which bind CD79UCB BIOPHARMA SPRL·Filed 2016·Granted Apr 14, 2020·9 cites·12 claims
- 0993US10370447B2Molecules with specificity for CD79 and CD22UCB BIOPHARMA SPRL·Filed 2015·Granted Aug 6, 2019·15 cites·11 claims
- 1093US8303953B2Antibody molecules which bind IL-17A and IL-17FADAMS RALPH·Filed 2007·Granted Nov 6, 2012·18 cites·12 claims
- 1192US11674967B2Method of identifying potential inhibitors of APO TNFα trimersUCB Biopharma SRL·Filed 2020·Granted Jun 13, 2023·2 cites·19 claims
- 1292US8057794B2Antibody molecules which bind to human IL-17RAPECKI STEPHEN EDWARD·Filed 2007·Granted Nov 15, 2011·26 cites·12 claims
- 1391US11472879B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2020·Granted Oct 18, 2022·2 cites·20 claims
- 1491US8231875B2Neutralising antibody molecules having specificity for human IL-17ADAMS RALPH·Filed 2005·Granted Jul 31, 2012·15 cites·9 claims
- 1590US10774152B2Molecules with specificity for CD45 and CD79UCB BIOPHARMA SPRL·Filed 2015·Granted Sep 15, 2020·5 cites·12 claims
- 1689US2025012807A1Mechanism of actionUCB Biopharma SRL·Filed 2024·Application pending·0 cites
- 1787US11261252B2Molecules with specificity for CD79 and CD22UCB Biopharma SRL·Filed 2019·Granted Mar 1, 2022·2 cites·10 claims
- 1886US8329431B2Nucleic acid molecules encoding neutralising antibodies having specificity for human IL-17ADAMS RALPH·Filed 2011·Granted Dec 11, 2012·6 cites·17 claims
- 1985US12474348B2Complexes between CD40 and compounds comprising benzimidazole moietiesUCB Biopharma SRL·Filed 2022·Granted Nov 18, 2025·0 cites·6 claims
- 2080US10208349B2Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacyUCB BIOPHARMA SPRL·Filed 2013·Granted Feb 19, 2019·5 cites·6 claims
- 2179US12331117B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2022·Granted Jun 17, 2025·0 cites·20 claims
- 2279US8435761B2DNA encoding antibody molecules which bind human IL-17RAPECKI STEPHEN EDWARD·Filed 2011·Granted May 7, 2013·4 cites·6 claims
- 2378US10308723B2Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17FUCB BIOPHARMA SPRL·Filed 2017·Granted Jun 4, 2019·1 cites·9 claims
- 2478US8865167B2Neutralising antibody molecules having specificity for human IL-17UCB PHARMA SA·Filed 2012·Granted Oct 21, 2014·2 cites·7 claims
- 2578US7931900B2Method for the treatment of multiple sclerosis by inhibiting IL-17 activityUCB PHARMA SA·Filed 2008·Granted Apr 26, 2011·5 cites·4 claims
- 2677US2021140972A1Mechanism of actionUCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 2774US9890219B2Methods of treating an IL-17A mediated pathological conditionUCB BIOPHARMA SPRL·Filed 2015·Granted Feb 13, 2018·1 cites·14 claims
- 2874US8617847B2Nucleic acids encoding antibody molecules which bind IL-17A and IL-17FUCB PHARMA SA·Filed 2012·Granted Dec 31, 2013·1 cites·17 claims
- 2971US2023287134A1Antibody molecules which bind cd45UCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 3065US2015147331A1Neutralising Antibody Molecules having Specificity for Human IL-17UCB PHARMA SA·Filed 2014·Application pending·0 cites
- 3164US2019322739A1Bispecific format suitable for use in high-through-put screeningUCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 3264US2014186355A1Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17FUCB PHARMA SA·Filed 2013·Application pending·0 cites
- 3363US2014044732A1Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17FUCB PHARMA SA·Filed 2013·Application pending·0 cites
- 3462US11466324B2Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacyUCB BIOPHARMA SPRL·Filed 2019·Granted Oct 11, 2022·0 cites·5 claims
- 3561US2017275355A1Neutralising antibody molecules having specificity for human il-17UCB BIOPHARMA SPRL·Filed 2017·Application pending·0 cites
- 3659US2023374148A1Binding molecules that multimerise cd45UCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 3758US11692041B2Antibody molecules which bind CD45UCB BIOPHARMA SPRL·Filed 2016·Granted Jul 4, 2023·0 cites·14 claims
- 3858US2016251429A1Neutralising antibody molecules having specificity for human il-17UCB PHARMA SA·Filed 2016·Application pending·0 cites
- 3957US2025388688A1Anti-tshr antibodies and uses thereofETHYREAL BIO INC·Filed 2025·Application pending·0 cites
- 4053US2019359713A1Molecules with specificity for cd45 and cd79UCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 4152US2023125234A1Anti cd44-ctla4 bispecific antibodiesUCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 4252US2023096030A1Bispecific antibodies against cd9 and cd7UCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 4352US2023192900A1Bispecific antibodies binding hvem and cd9UCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 4452US2023151109A1Bispecific antibodies against cd9UCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 4552US2023151108A1Bispecific antibodies against cd9 and cd137UCB Biopharma SRL·Filed 2020·Application pending·0 cites
- 4648US2007269428A1Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 ActivityCELLTECH R&D LTD·Filed 2004·Application pending·0 cites
- 4739US2016159922A1Novel Antibodies for the Diagnosis and Treatment of Rheumatoid ArthritisVILARA AB·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Edward Rapecki files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →